We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Akebia Therapeutics (AKBA - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Akebia Therapeutics is one of 983 individual stocks in the Medical sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Akebia Therapeutics is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AKBA's full-year earnings has moved 34.4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, AKBA has returned 94% so far this year. In comparison, Medical companies have returned an average of -7.8%. This means that Akebia Therapeutics is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Alignment Healthcare (ALHC - Free Report) . The stock has returned 22.5% year-to-date.
In Alignment Healthcare's case, the consensus EPS estimate for the current year increased 5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Akebia Therapeutics belongs to the Medical - Drugs industry, a group that includes 154 individual stocks and currently sits at #90 in the Zacks Industry Rank. On average, this group has gained an average of 3.6% so far this year, meaning that AKBA is performing better in terms of year-to-date returns.
On the other hand, Alignment Healthcare belongs to the Medical Services industry. This 58-stock industry is currently ranked #85. The industry has moved -7.7% year to date.
Investors with an interest in Medical stocks should continue to track Akebia Therapeutics and Alignment Healthcare. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Akebia Therapeutics (AKBA - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Akebia Therapeutics is one of 983 individual stocks in the Medical sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Akebia Therapeutics is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AKBA's full-year earnings has moved 34.4% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, AKBA has returned 94% so far this year. In comparison, Medical companies have returned an average of -7.8%. This means that Akebia Therapeutics is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Alignment Healthcare (ALHC - Free Report) . The stock has returned 22.5% year-to-date.
In Alignment Healthcare's case, the consensus EPS estimate for the current year increased 5% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, Akebia Therapeutics belongs to the Medical - Drugs industry, a group that includes 154 individual stocks and currently sits at #90 in the Zacks Industry Rank. On average, this group has gained an average of 3.6% so far this year, meaning that AKBA is performing better in terms of year-to-date returns.
On the other hand, Alignment Healthcare belongs to the Medical Services industry. This 58-stock industry is currently ranked #85. The industry has moved -7.7% year to date.
Investors with an interest in Medical stocks should continue to track Akebia Therapeutics and Alignment Healthcare. These stocks will be looking to continue their solid performance.